About Us | Contact Us |        

A Performance Measures-Based Patient-Centric Approach to IBD

A Performance Measures-Based Patient-Centric Approach to IBD
1 AMA PRA Category 1 Credit(s)
Launch Date:
October 13, 2015
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Physicians, Nurse Practioners, Physican Assistants

Relevant Terms:

Inflammatory Bowel Diseases

Adam S. Cheifetz, MD

​Adam S. Cheifetz, MD
Director, Inflammatory Bowel Disease Program, Beth Israel Deaconess Medical Center
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Adam S. Cheifetz, MD, is the director of the Inflammatory Bowel Disease Program at Beth Israel Deaconess Medical Center and an associate professor of medicine at Harvard Medical School. Dr. Cheifetz graduated magna cum laude from Brown University in Rhode Island before earning his MD from Cornell University Medical College in New York. He completed his internship and residency in internal medicine at Yale-New Haven Hospital in Connecticut and his fellowship in gastroenterology at Yale University before serving as the Present-Levison Fellow in Inflammatory Bowel Disease at the Mount Sinai Medical Center in New York.

Dr. Cheifetz specializes in the treatment of Crohn's disease, ulcerative colitis, and other inflammatory bowel diseases (IBD). For the last 8 years, he has been cited in Boston Magazine as one of Boston's "Top Doctors." In addition to his clinical work, he is involved in multiple research projects relating to IBD and has published more than 100 articles and chapters on the subject. Dr. Cheifetz's research currently focuses on optimizing the use of biologics through the proactive use of drug concentrations and antibodies. He lectures nationally and internationally on IBD and has been involved with the Crohn's and Colitis Foundation of America (CCFA) for more than 10 years on both a regional and national level.

Dr. Cheifetz is actively involved with teaching and mentoring medical students, residents, and fellows, and is proud to have trained numerous physicians who now specialize in IBD. He is director of the Harvard Medical School Gastroenterology Clerkship Elective and assistant director of the Advanced Fellowship in Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center. In addition, he serves on numerous editorial boards, including Inflammatory Bowel Diseases, Journal of Clinical Gastroenterology, Journal of Crohn's and Colitis, and World Journal of Gastroenterology.
1. Compare and contract the clinical effects of inflammatory bowel disease (IBD) therapies
2. Select individualized treatments for patients with IBD that maximize the opportunity to achieve remission and avoid relapse while minimizing toxicity
3. Employ ongoing monitoring strategies assessing treatment goals and implement changes in treatment plans as appropriate
4. Utilize AGA practice measures for the management of IBD patients to slow the disease course and minimize complications

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
  • Adam S. Cheifetz, MD, has affiliations with AbbVie, Janssen, UCB, Pfizer, Prometheus Laboratories, and Takeda (Consulting); Royalty-Up To Date.
  • Boris Rozenfeld, MD, has no affiliations with commercial interests to disclose.
  • Amy Reeve has no affiliations with commercial interests relative to the content to disclose.
Postgraduate Institute for Medicine
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, MSN, RN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Estimated time to complete: 1.0 hour
Medium: Internet

There is no fee for this educational activity.

This activity is supported by an independent educational grant from AbbVie.

By reviewing the course content and successfully completing the self-assessment and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.
Physicians, nurse practitioners, and physician assistants who successfully complete the self-assessment and evaluation will receive CME/CE credit. You must score 65% or higher on the self-assessment to receive credit for this activity. All other participants who successfully complete the self-assessment and evaluation will receive a certificate of participation.
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.